Ads
related to: rapid acting insulin action
Search results
Results from the WOW.Com Content Network
Glulisine is rapid acting insulin analog from Sanofi-Aventis, approved for use with a regular syringe, in an insulin pump. Standard syringe delivery is also an option. It is sold under the name Apidra. The FDA-approved label states that it differs from regular human insulin by its rapid onset and shorter duration of action. [3]
This basal rate of insulin action is generally achieved via the use of an intermediate-acting insulin (such as NPH) or a long-acting insulin analog. In type 1 diabetics, it may also be achieved via continuous infusion of rapid-acting insulin using an insulin pump. Approximately half of a person's daily insulin requirement is administered as a ...
Insulin glulisine, sold under the brand name Apidra among others, is a rapid-acting modified form of medical insulin used for the treatment of diabetes.It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. [2]
It has a duration of action that lasts up to 42 hours (compared to 18 to 26 hours provided by other marketed long-acting insulins such as insulin glargine and insulin detemir), making it a once-daily basal insulin, [8] [9] [10] that is one that provides a base insulin level, as opposed to the fast- and short-acting bolus insulins. Insulin ...
The U.S. Food and Drug Administration has approved a fast-acting diabetes drug called Afrezza for use by adults with Type 1 or Type 2 diabetes. The drug is inhaled into the lungs using a small ...
The insulin aspart protamine portion is a crystalline form of insulin aspart, which delays the action of the insulin, giving it a prolonged absorption profile after injection. [14] The combination of the fast-acting form and the long-acting form allows the patient to receive fewer injections over the course of the day. [27]
Ads
related to: rapid acting insulin action